This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (571)

Published on in Vol 8, No 8 (2019): August

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/14636, first published .
Safety and Efficacy of Bis-Glyceryl Ascorbate (Amitose DGA) to Prevent Hand-Foot Skin Reaction in Patients With Renal Cell Carcinoma Receiving Sunitinib Therapy: Protocol for a Phase I/II, Uncontrolled, Single-Arm, Open-Label Trial

Safety and Efficacy of Bis-Glyceryl Ascorbate (Amitose DGA) to Prevent Hand-Foot Skin Reaction in Patients With Renal Cell Carcinoma Receiving Sunitinib Therapy: Protocol for a Phase I/II, Uncontrolled, Single-Arm, Open-Label Trial

Safety and Efficacy of Bis-Glyceryl Ascorbate (Amitose DGA) to Prevent Hand-Foot Skin Reaction in Patients With Renal Cell Carcinoma Receiving Sunitinib Therapy: Protocol for a Phase I/II, Uncontrolled, Single-Arm, Open-Label Trial

Authors of this article:

Kazuhiro Yamamoto1 Author Orcid Image ;   Takeshi Ioroi1 Author Orcid Image ;   Kenichi Harada2 Author Orcid Image ;   Satoshi Nishiyama3 Author Orcid Image ;   Chikako Nishigori3 Author Orcid Image ;   Ikuko Yano1 Author Orcid Image
Article Authors Cited by (1) Tweetations (1) Metrics

Kazuhiro Yamamoto   1 , PhD ;   Takeshi Ioroi   1 , PhD ;   Kenichi Harada   2 , MD, PhD ;   Satoshi Nishiyama   3 , MD, PhD ;   Chikako Nishigori   3 , MD, PhD ;   Ikuko Yano   1 , PhD

1 Department of Pharmacy, Kobe University Hospital, Kobe, Japan

2 Department of Urology, Graduate School of Medicine, Kobe University, Kobe, Japan

3 Division of Dermatology, Department of Internal Related, Graduate School of Medicine, Kobe University, Kobe, Japan

Corresponding Author: